Winner Medical(SZ:300888) Guohai Securities·2025-11-04 08:31Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has achieved continuous high-quality growth in the first three quarters of 2025, with a revenue of 7.897 billion yuan, representing a year-on-year increase of 30.10%. The net profit attributable to the parent company reached 732 million yuan, up 32.36% year-on-year [4][6] - The medical segment reported a revenue of 3.83 billion yuan in Q1-Q3 2025, a year-on-year growth of 44.4%, driven by rapid development in core categories such as surgical consumables and high-end dressings [4][6] - The consumer segment generated a revenue of 4.01 billion yuan in Q1-Q3 2025, with a year-on-year increase of 19.1%, led by strong sales of specific products like sanitary napkins [4][6] Summary by Sections Recent Performance - In Q3 2025, the company achieved a revenue of 2.601 billion yuan, a year-on-year increase of 27.71%, and a net profit of 240 million yuan, up 42.11% year-on-year [4] - The company’s stock performance over the past year shows a 30.4% increase, outperforming the CSI 300 index [3] Medical Segment - The medical segment's revenue for Q1-Q3 2025 was 3.83 billion yuan, with significant growth in surgical consumables (185.3% increase), high-end dressings (26.2% increase), and health personal care products (24.6% increase) [4] - International sales channels contributed 2.18 billion yuan, marking an 81.7% year-on-year growth, with a notable increase in Southeast Asia and the Middle East [4] Consumer Segment - The consumer segment's revenue reached 4.01 billion yuan in Q1-Q3 2025, with the fastest growth seen in sanitary napkins, which generated 760 million yuan, a 63.9% increase [4] - E-commerce channels showed robust growth, achieving 2.46 billion yuan in revenue, a 23.5% increase, with significant contributions from interest e-commerce platforms [4] Financial Forecast - The company is projected to achieve revenues of 11.511 billion yuan in 2025, with a net profit of 995 million yuan, reflecting a growth rate of 28% and 43% respectively [6][7] - The estimated P/E ratios for the next few years are 23.93 for 2025, 20.35 for 2026, and 17.49 for 2027, indicating a favorable valuation trend [6][7]